Most people with relapsing MS who were treated with Briumvi for six years did not have confirmed disability progression, a study found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback